FDA Enforcing Rx Compounding Regs Pending Supreme Court Ruling
Executive Summary
FDA will continue to enforce the pharmacy compounding provisions of the FDA Modernization Act until the Supreme Court rules on a lower court decision that the compounding section is invalid
You may also be interested in...
FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say
FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26
FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say
FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26
FDA’s 2002 Regulatory Agenda, In Brief
IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...